Document is current
Any future updates will be listed below
-
Authors
Dharan, Nila J.
Yeh, Paul
Bloch, Mark
Yeung, Miriam M. https://orcid.org/0000-0002-9455-1887
Baker, David
Guinto, Jerick
Roth, Norman
Ftouni, Sarah
Ognenovska, Katherine
Smith, Don
Hoy, Jennifer F. https://orcid.org/0000-0002-6948-7086
Woolley, Ian https://orcid.org/0000-0003-2928-1291
Pell, Catherine
Templeton, David J. https://orcid.org/0000-0003-2157-9587
Fraser, Neil
Rose, Nectarios
Hutchinson, Jolie
Petoumenos, Kathy https://orcid.org/0000-0001-7534-7154
Dawson, Sarah-Jane https://orcid.org/0000-0002-8276-0374
Polizzotto, Mark N. https://orcid.org/0000-0002-6446-183X
Dawson, Mark A. https://orcid.org/0000-0002-5464-5029
,
Vincent, Trina
Rosario, Ricardo
Lau, Helen
Smith, Denise
Price, Sally
O’Brien, Jessica
Tan, Hooi Theng Lynn
Sinclair, Bret
Bascombe, Florence
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1196749, 1128984, Post graduate scholarship, 1195030, 1196755, 1128984, 1110067, 1213110)
Cancer Council Victoria (Dunlop Fellowship)
Howard Hughes Medical Institute (International research scholarship)
Snowdome/Maddie Riewoldt’s Vision FellowshipGilead Fellowship
CSL Centenary fellowship
Cancer Institute of NSW Future Research Leader Fellowship
- License Information
-
More Information
Article History
Received: 11 November 2020
Accepted: 19 April 2021
First Online: 7 June 2021
Competing interests
: M.A.D. has been a member of advisory boards for CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. S.-J.D has been a member of advisory boards for AstraZeneca. The laboratory of S.-J.D. received funding from CTx CRC and Genentech. The laboratory of M.A.D. received research funding from CTx CRC. N.J.D. received research support from Gilead Sciences. D.S. received research support and consultancy fees from Gilead Sciences, Janssen pharmaceuticals and Merck. J.H.’s institution received reimbursement for her involvement in Advisory Boards for Gilead Sciences, Merck, Sharp & Dohme and ViiV Healthcare. M.B. received support for medical advisory boards, lecturing and attendance at scientific conferences from Gilead Sciences, ViiV Healthcare and AbbVie, and his institution has received research support from Gilead Sciences, ViiV Healthcare, GSK, AbbVie, MSD, Amgen and Eli Lilly.
